The effect of levetiracetam on rat bone mass, structure and metabolism

Epilepsy Research

Volumn 107, Issue 1-2, 2013, Pages 56-60

  Fekete, Sona ^a   Simko, Julius ^a   Gradosova, Iveta ^a   Malakova, Jana ^a   Zivna, Helena ^a   Palicka, Vladimir ^a   Zivny, Pavel ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Antiepileptic drugs; Bone markers; Bone mineral density; Levetiracetam

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 2; CARBOXY TERMINAL TELOPEPTIDE; ETIRACETAM; OSTEOPROTEGERIN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BONE DENSITY; BONE HOMOGENATE; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE STRENGTH; BONE STRUCTURE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; EPILEPSY; FEMUR; HOMOGENATE; LUMBAR SPINE; MALE; MUSCULOSKELETAL FUNCTION; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIEPILEPTIC DRUGS; BONE MARKERS; BONE MINERAL DENSITY; LEVETIRACETAM;

ALKALINE PHOSPHATASE; ANIMALS; BIOLOGICAL MARKERS; BODY COMPOSITION; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEIN 2; COLLAGEN TYPE I; MALE; OSTEOPROTEGERIN; PIRACETAM; RATS; RATS, WISTAR;

EID: 84886950062     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2013.08.012     Document Type: Article

References (20)

1. Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors?. Seizure 2008, 17:181-186.
2. Heo K., Rhee Y., Lee S.A., et al. The effect of topiramate on bone mineral density and markers of bone mineral metabolism in premenopausal women with epilepsy. Epilepsia 2011, 52(10):1884-1889.
3. Ali I.I., Herial N.A., Orris M., et al. Migraine prophylaxis with topiramate and bone health in women. Headache 2011, 51(4):613-616.
4. Takahashi A., Onodera K., Kamei J., Sakurada S., Shinoda H., Miyazaki S., Saito T., Mayanagi H. Effect of chronic administration of zonisamide, an antiepileptic drug, on bone mineral density and their prevention with alfacalcidol in growing rats. J. Pharm. Sci. 2003, 91:313-318.
5. Babacan O., Karaoglu A., Vurucu S., Yesilkaya E., Yesilyurt O., Cayci T., Gulgun M., Unay B., Akin R., Ozcan O. May long term oxcarbazepine treatment be lead to secondary hyperparathyroidism?. J. Clin. Neurol. 2012, 8:65-68.
6. Cansu A., Yesilkaya E., Serdaroǧlu A., Hirfanoǧlu T.L., Camurdan O., Gülbahar O., Gücüyener K., Cinaz P. Evaluation of bone turnover in epileptic children using oxcarbazepine. Pediatr. Neurol. 2008, 39:266-271.
7. Mintzer S., Boppana P., Toguri J., DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 1996, 47:510-515.
8. Ensrud K.E., Walczak T.S., Blackwell T.L., Ensrud E.R., Barrett-Connor E., Orwoll E.S. Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology 2008, 71:723-730.
9. Nissen-Meyer L.S., Svalheim S., Taubřll E., Reppe S., Lekva T., Solberg L.B., Melhus G., Reinholt F.P., Gjerstad L., Jemtland R. Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. Epilepsia 2007, 48(10):1850-1860.
10. Beniczky S.A., Viken J., Jensen L.T., Andersen N.B. Bone mineral density in adult patients treated with various antiepileptic drugs. Seizure 2012, 21(6):471-472.
11. Koo D.L., Joo E.Y., Kim D., Hong S.B. Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy. Epilepsy Res. 2013, 104(1-2):134-139.
12. Lancelin F., Franchon E., Kraoul L., Garciau I., Brovedani S., Tabaouti K., Landré E., Chassoux F., Paubel P., Piketty M. Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviole detection: preliminary observations on correlation between plasma concentration and clinical response in patient with refractory epilepsy. Ther. Drug Monit. 2007, 29(5):576-583.
13. Gradosova I., Zivna H., Svejkovska K., Palicka V., Tichy M., Zivny P. The role of atorvastatin in bone metabolism in male albino Wistar rats. Pharmazie 2011, 66:606-610.
14. Isojarvi J.I., Tauboll E., Herzog A.G. Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. CNS Drugs 2005, 19(3):207-223.
15. Rattya J., Pakarinen A.J., Knip M. Early hormonal changes during valproate or carbamazepine treatment: a 3-month study. Neurology 2001, 57(3):440-444.
16. Pack A.M., Morrell M.J., McMahon D.J., Shane E. Normal vitamin D and low free estradiol levels in women on enzyme-inducing antiepileptic drugs. Epilepsy Behav. 2011, 21(4):453-458.
17. Svalheim S., Tauboll E., Surdova K., et al. Long-term levetiracetam treatment affects reproductive endocrine function in female Wistar rats. Seizure 2008, 17:203-209.
18. Vandenput L., Boonen S., Van Herck E., Swinnen J.V., Bouillon R., Vanderschueren D. Evidence from the aged orchidectomized male rat model that 17 beta-estradiol is a more effective bone-sparing and anabolic agent than 5 alpha-dihydrotestosterone. J. Bone Miner. Res. 2002, 17(11):2080-2086.
19. Callewaert F., Sinnesael M., Gielen E., Boonen S., Vanderschueren D. Skeletal sexual dimorphism: relative contribution of sex steroids, GH-IGF1, and mechanical loading. J. Endocrinol. 2010, 207(2):127-134.
20. Phabphal K., Geater A., Limapichat K., Sathirapanya P., Setthawatcharawanich S., Leelawattana R. Effect of switching hepatic enzyme-inducer antiepileptic drug to levetiracetam on bone mineral density, 25 hydroxyvitamin D, and parathyroid hormone in young adult patients with epilepsy. Epilepsia 2013, 54(6):94-98.